Montelukast Accord Healthcare (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition reduces airway narrowing, mucus production, and inflammation that are mediated by leukotrienes, thereby improving breathing and reducing allergic symptoms.

The appropriate dose is determined by the prescribing clinician based on the patient’s age, condition, and response to therapy. Montelukast is typically taken once daily in the evening, but exact dosing should follow the prescriber’s instructions.

Safety data for Montelukast in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk. Likewise, it is excreted in breast milk, so breastfeeding mothers should discuss risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Montelukast and inhaled corticosteroids (ICS) target different aspects of asthma control. Montelukast blocks leukotriene‑mediated inflammation, while ICS reduce a broader range of inflammatory pathways. Montelukast is often used as an add‑on therapy for patients who remain symptomatic on low‑dose ICS or who have specific allergic components, but it is not a substitute for high‑dose ICS in severe asthma.

The tablets should be stored at temperatures below 25 °C, in their original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Montelukast Accord Healthcare is taken orally, usually as a whole tablet swallowed with water. It is commonly prescribed for once‑daily dosing in the evening, but patients should follow the specific timing advised by their prescriber.

Serious adverse reactions, although rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, and hepatic injury. Patients should seek immediate medical attention if they experience swelling of the face or throat, rash with blistering, or signs of liver dysfunction such as jaundice.

Montelukast is contraindicated in individuals with a known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in those who have experienced serious allergic reactions to leukotriene‑modifying agents.